A phase 1/2 study called TACTOPS investigated a new treatment for pancreatic cancer based on autologous T-cell therapy. This treatment targets five antigens: PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1. The study was published in the journal Nature Medicine on January 2, 2026. The results show that this therapy was safe and led to a clinical response in patients with pancreatic ductal adenocarcinoma. The treatment induced a safe immune response against the target antigens. This study represents a potential advance in the treatment of pancreatic cancer, which is known to be an extremely difficult disease with a low survival rate.